Market Closed - Australian S.E. 02:10:52 2024-04-24 am EDT 5-day change 1st Jan Change
2.09 AUD +2.45% Intraday chart for PolyNovo Limited +2.45% +26.28%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Polynovo Gets India OK for Listing of Dermal Scaffold Device on Government e-Portal Marketplace MT
Transcript : PolyNovo Limited, H1 2024 Earnings Call, Feb 27, 2024
PolyNovo Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
PolyNovo Secures Largest Single Order Worth AU$1.2 Million; Shares Rise 3% MT
PolyNovo Logs Record Monthly Sales in November MT
PolyNovo Limited Reports Unaudited Sales Results for the Month of November 2023 CI
Transcript : PolyNovo Limited - Shareholder/Analyst Call
Polynovo Secures Additional Funding from BARDA for Burn Treatment Trial MT
Transcript : PolyNovo Limited, 2023 Earnings Call, Aug 23, 2023
PolyNovo Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Immuron Appoints Paul Brennan as Board Chairman MT
PolyNovo Limited Reports Revenue Results for the Month and Nine Months Ended 31 March 2023 CI
PolyNovo Limited(ASX:PNV) added to S&P/ASX 200 Index CI
Polynovo Swings to Net Loss in Fiscal H1 on Employee, R&D Expansion; Shares Fall 4% MT
Transcript : PolyNovo Limited, H1 2023 Earnings Call, Feb 23, 2023
PolyNovo Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial CI
Transcript : PolyNovo Limited - Shareholder/Analyst Call
PolyNovo Limited Provides Unaudited Revenues Results for the First Half 2023 CI
Transcript : PolyNovo Limited Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-11-2023 07:30 AM
Polynovo to Raise AU$20 Million from Share Purchase Plan MT
Transcript : PolyNovo Limited - Pre Recorded Special Call
Polynovo Kicks Off $11 Million Share Offering MT
PolyNovo to Raise $20 Million in Institutional Placement; Shares Slip 9% MT
PolyNovo Requests Trading Halt MT
Chart PolyNovo Limited
More charts
PolyNovo Limited is an Australia-based company, which is engaged in the development of medical devices for various medical applications, utilizing the patented bioabsorbable polymer technology NovoSorb. Its products include NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb technology. BTM product is designed to help surgeons treat traumatic wounds. NovoSorb BTM may be used to temporarily close the wound and aid the body in generating new tissue. It is indicated for full or deep partial-thickness burns, surgical and reconstructive wounds and traumatic wounds. BTM is applied to a wound once the unhealthy or dead tissue has been surgically removed. NovoSorb is a medical-grade polymers that can be expressed in a range of physical formats. NovoSorb polymers have advantageous properties such as biocompatibility and design flexibility. These properties underpin novel medical devices designed to support tissue repair, before they biodegrade in situ into biocompatible by-products.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
2.09 AUD
Average target price
2.113 AUD
Spread / Average Target
+1.12%
Consensus
  1. Stock Market
  2. Equities
  3. PNV Stock
  4. News PolyNovo Limited
  5. Polynovo Ropes in Former Director as Interim CEO